+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor



Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor



Urology 78(3): 511-514



To evaluate the frequency and potential risk factors for infection-related complications after transrectal prostate biopsy and to propose adjustments in current antimicrobial prophylaxis recommendations. During 2008-2010, 107 patients underwent transrectal ultrasound-guided biopsies of the prostate at our institution. Charts were reviewed for infection-related complications within 30 days of the procedure. Potential risk factors were evaluated, including age, diabetes mellitus, chronic constipation/diverticular disease, prior use of quinolones, enema and prostatitis, on the pathology report. For patients with acute prostatitis, urine and blood samples were assessed for bacteriology and antibiotic susceptibility. Of our 107 patients, acute prostatitis developed in 10 (9.3%). The most significant risk factor was prior use of a fluoroquinolone antimicrobial, with acute prostatitis developing in 7 (17.1%) of 41 patients who had used a fluoroquinolone compared with 3 (4.5%) of 66 patients who had not (P=.042). Patients who received an enema before the procedure were slightly less likely to develop prostatitis (P=.061). Of 8 positive specimens, the organisms isolated were Escherichia coli in 6, Klebsiella pneumoniae in 1, and Staphylococcus epidermidis in one. Isolated Gram-negative organisms were fluoroquinolone-resistant in 85.7% of samples. Prior fluoroquinolone intake is a significant risk factor behind a rising incidence of acute prostatitis after transrectal prostate biopsy. Identified pathogens are mostly Gram-negative organisms with a high rate of fluoroquinolone resistance. Alternative prophylaxis regimens for the biopsy procedure should be considered in patients with recent quinolone intake.

(PDF emailed within 0-6 h: $19.90)

Accession: 055577306

Download citation: RISBibTeXText

PMID: 21782225

DOI: 10.1016/j.urology.2011.04.064


Related references

Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy. Urology 78(6): 1235-1239, 2012

Re: Prevalence of fluoroquinolone-resistant Escherichia coli before and Incidence of acute bacterial prostatitis after prostate biopsy. Journal of Urology 188(1): 122-123, 2012

Positive culture for extended-spectrum β-lactamase during acute prostatitis after prostate biopsy is a risk factor for progression to chronic prostatitis. Urology 81(6): 1209-1212, 2013

Fluoroquinolone-resistant acute prostatitis requiring hospitalization after transrectal prostate biopsy: effect of previous fluoroquinolone use as prophylaxis or long-term treatment. International Urology and Nephrology 44(1): 19-27, 2012

Re: Clinical and Microbiological Characteristics of Spontaneous Acute Prostatitis and Transrectal Prostate Biopsy-Related Acute Prostatitis: Is Transrectal Prostate Biopsy-Related Acute Prostatitis a Distinct Acute Prostatitis Category?. Journal of Urology 196(3): 755-756, 2016

Clinical and microbiological characteristics of spontaneous acute prostatitis and transrectal prostate biopsy-related acute prostatitis: Is transrectal prostate biopsy-related acute prostatitis a distinct acute prostatitis category?. Journal of Infection and ChemoTherapy 21(6): 434-437, 2016

Risk factors for acute prostatitis after transrectal biopsy of the prostate. Korean Journal of Urology 51(6): 426-430, 2010

The incidence and risk factors of resistant E. coli infections after prostate biopsy under fluoroquinolone prophylaxis: a single-centre experience with 2215 patients. Journal of ChemoTherapy 28(4): 284-288, 2017

Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy. Urology 74(1): 119-123, 2009

Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology 72(5): 1102-1105, 2008

Diagnostic investigations of canine prostatitis incidence together with benign prostate hyperplasia, prostate malignancies, and biochemical recurrence in high-risk prostate cancer as a model for human study. Tumour Biology 36(4): 2437-2445, 2015

Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures. Archives of Ophthalmology 129(4): 399-402, 2011

The incidence of fluoroquinolone resistant infections after prostate biopsy - Are fluoroquinolones still effective prophylaxis?. Journal of Urology 179(3): 952-955, 2008

Retraction Note to: Diagnostic investigations of canine prostatitis incidence together with benign prostate hyperplasia, prostate malignancies, and biochemical recurrence in high-risk prostate cancer as a model for human study. Tumour Biology, 2016